All The Lundquist Institute articles
-
NewsStrategic advancement of second-generation fungal vaccine VXV-01 through Phase 1 trials
The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) have announced that the second-generation fungal vaccine candidate known as VXV‑01 is poised to move forward in development up to and including Phase 1 clinical evaluation.